192,950 Shares in Avanos Medical, Inc. $AVNS Purchased by Trexquant Investment LP

Key Points

• Trexquant Investment LP acquired 192,950 shares of Avanos Medical, Inc. for approximately $2,765,000, representing about 0.42% of the company's stock.
• Several institutional investors, including the State of Wyoming and Tower Research Capital LLC, significantly increased their positions in Avanos Medical during the fourth quarter.
• Avanos Medical recently reported earnings of $0.17 per share, missing estimates, while also providing FY 2025 guidance of $0.750-0.950 EPS.

Trexquant Investment LP bought a new stake in Avanos Medical, Inc. (NYSE:AVNS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 192,950 shares of the company's stock, valued at approximately $2,765,000. Trexquant Investment LP owned approximately 0.42% of Avanos Medical as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. State of Wyoming boosted its stake in Avanos Medical by 132.0% during the fourth quarter. State of Wyoming now owns 5,137 shares of the company's stock valued at $82,000 after buying an additional 2,923 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Avanos Medical by 493.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock worth $129,000 after buying an additional 6,714 shares during the period. EP Wealth Advisors LLC raised its position in Avanos Medical by 14.6% in the 4th quarter. EP Wealth Advisors LLC now owns 10,108 shares of the company's stock valued at $161,000 after purchasing an additional 1,289 shares during the last quarter. Heritage Family Offices LLP bought a new stake in shares of Avanos Medical during the first quarter worth $146,000. Finally, Mariner LLC grew its stake in Avanos Medical by 18.0% in the fourth quarter. Mariner LLC now owns 10,655 shares of the company's stock valued at $170,000 after acquiring an additional 1,625 shares during the period. 95.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AVNS. Zacks Research upgraded Avanos Medical to a "hold" rating in a research note on Tuesday, August 12th. Wall Street Zen lowered Avanos Medical from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Hold".

Insider Buying and Selling at Avanos Medical

In related news, Director Gary Blackford acquired 40,000 shares of the firm's stock in a transaction on Wednesday, August 13th. The shares were acquired at an average cost of $10.99 per share, with a total value of $439,600.00. Following the completion of the acquisition, the director directly owned 40,000 shares in the company, valued at approximately $439,600. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.64% of the stock is owned by insiders.

Avanos Medical Stock Performance

Shares of Avanos Medical stock traded down $0.28 on Monday, hitting $12.45. 214,147 shares of the company's stock were exchanged, compared to its average volume of 539,661. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $25.36. The company has a 50-day simple moving average of $11.63 and a 200-day simple moving average of $12.67. The stock has a market capitalization of $577.45 million, a PE ratio of -1.24 and a beta of 1.12.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. Avanos Medical had a negative net margin of 66.89% and a positive return on equity of 6.16%. During the same quarter in the prior year, the firm posted $0.34 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.750-0.950 EPS. As a group, equities analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.